You are here: Industry Insights > Novartis

News List

Novartis' Global Innovative siRNA Long-Acting Lipid-lowering Therapy Submitted Clinical Application in China PharmaSources/Xiaoyaowan
July 01, 2020
On June 28, the CDE official website showed that Novartis' siRNA long-acting lipid-lowering drug Inclisiran submitted a clinical application in China and has been accepted and accepted.
Novartis seeks FDA EUA for Covid-19 antiviral candidate ensovibep Pharmaceutical-Technology
February 14, 2022
Molecular Partners has reported that its partner Novartis sought emergency use authorization (EUA) for the antiviral candidate, ensovibep, from the US Food and Drug Administration (FDA) to treat Covid-19.
Novartis India extends access to its medicines in India with Dr Reddy’s Laboratories ExpressPharma
February 14, 2022
Novartis India recently announced an exclusive sales and distribution agreement with Dr Reddy’s Laboratories for a few of its established medicines which include the Voveran range, the Calcium range and Methergine, Novartis notified via a statement.
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 WorldPharmaNews
January 13, 2022
Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo to treat COVID-19...
Novartis and Molecular Partners report positive topline data from phase-II study for Ensovibep ExpressPharma
January 11, 2022
The secondary endpoint of hospitalisation and/or ER visits related to COVID-19, or death showed an overall 78 per cent reduction in risk of events across Ensovibep arms compared to placebo.
Novartis to acquire UK’s Gyroscope Therapeutics for up to $1.5bn Pharmaceutical-Technology
December 24, 2021
Novartis has signed a definitive agreement for the acquisition of all the outstanding shares of UK’s ocular gene therapy firm Gyroscope Therapeutics, in a deal worth up to $1.5bn.
Novartis signs deal with BeiGene to bolster immunotherapy pipeline Pharmaceutical-Technology
December 22, 2021
Novartis has entered an option, partnership and licence agreement for BeiGene’s anti-cancer therapy, ociperlimab (BGB-A1217), bolstering its research and development works in immuno-oncology.
Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021 WorldPharmaNews
December 21, 2021
Novartis announced the introduction of T-Charge™, the company's next-generation CAR-T platform that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline.
Novartis Announces Agreement with BeiGene for TIGIT Inhibitor Ociperlimab AmericanPharmaceuticalReview
December 21, 2021
Novartis announced the signing of an option, collaboration and license agreement with BeiGene, Ltd. for ociperlimab (BGB-A1217), expanding the company’s research and development activities in immuno-oncology.
Oxford Biomedica and Novartis extend lentiviral vector manufacturing agreement CPhIonline
December 15, 2021
The new agreement extends to 2028 and allows Oxord Biomedica to work with other potential partners across all CAR-T targets

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page